Video
Author(s):
“The take-home message here is that adjuvant nivolumab improves disease-free survival in patients with muscle-invasive urothelial cancer at high risk for recurrence after surgery,” says Matthew D. Galsky, MD.
In this video, Matthew D. Galsky, MD, discusses the takeaways and further research associated with the study, “Disease-free survival with longer follow-up from the phase 3 Checkmate 274 trial of adjuvant nivolumab in patients who underwent surgery for high-risk muscle-invasive urothelial carcinoma,” which was presented at the 2021 Society of Urologic Oncology Annual Meeting. Galsky is a professor of medicine and director of genitourinary medical oncology at the Icahn School of Medicine, Mount Sinai, and the co-director of the Center of Excellence for Bladder Cancer and associate director for translational research at the Tisch Cancer Institute in New York City, New York.
Upper tract urothelial carcinoma: An in-depth review for urologists
Upper tract urothelial carcinoma: An in-depth review for urologists
2 Commerce Drive
Cranbury, NJ 08512